EBSdart: A New Scale for Epidermolysis Bullosa Simplex Severity

EBSdart, a photo‑anchored five‑point severity scale for epidermolysis bullosa simplex, offers a standardized measure that could tighten clinical monitoring and improve trial outcome precision.

The investigators reviewed a repository of 130 clinical photographs from 80 genetically confirmed EBS patients. Nine board‑certified dermatologists independently scored images across five anatomical regions using a 5‑point scale; the team then derived EBSdart by consensus to capture the core disease features of blistering, erosions, and keratoderma. E

BSdart is disease‑specific and photo‑anchored, emphasizing EBS‑relevant domains rather than generalized skin indices. It can support routine disease monitoring, provide a standardized outcome measure for interventional studies and serve as a potential facilitator for regulatory submissions.

The tool captures core disease features and could improve trial outcome accuracy, and the team suggests it may accelerate FDA approval pathways for new therapies.